Strengths of our study, however, include focusing on PR3-ANCA+ GPA patients with little or no immunosuppression, and in our phenotype study, all patients with active disease were sampled before high-dose corticosteroid and cytotoxic treatment was started. This evidence concerns the gene PRTN3 and granulomatosis with polyangiitis.